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Abstract
Background: The diagnosis of Parkinson’s disease (PD), which is needed for useful symptomatic therapy, is based
on clinical criteria. However, it became quite clear in recent years that the same features can occur through different
etiopathogenic mechanisms. Even a pathological diagnosis of PD, based on the demonstration of α-synuclein deposits
in a typical distribution, can result from different causes and, vice versa, nigral cell loss can occur without α-synuclein
deposition.
Discussion: Thus far, attempts to influence the progression of PD have failed. However, since the clinical
manifestations of PD can be the result of diverse mechanisms, a single intervention may not be able to slow
the course of the disease in all patients. Indeed, targeting the underlying pathogenic processes, which differ among
cases, may be more effective. PD may develop as a consequence of mitochondrial damage, which itself may result
from a variety of genetic or environmental factors. Correction of the ensuing oxidative stress may theoretically be
useful in these PD patients, but will not affect the progression of the disease among other PD patients in whom an
identical clinical syndrome derives from defects in other pathways such as the ubiquitin-proteasome system and
lysosomal dysfunction, among others.
Summary: Precision medicine can now be used to identify the underlying pathogenic mechanisms in individual
patients, paving the way to the development of real disease modification through a pathway-oriented approach,
aimed at the underlying biologic processes of disease occurrence and evolution.
Keywords: Disease course modification, Disease modifying therapies, Parkinson’s disease, Pathogenesis, Precision
medicine, Therapy
Background
Huge investments in research have dramatically increased
our understanding of the biochemical and pathological
processes underlying neurodegenerative diseases. Never-
theless, thus far, these advances have failed to be translated
into breakthroughs in the treatment of any of these dis-
eases. The impressive progress over the past two decades
is the result of improved techniques in neuropathology,
genetics and imaging, and the development of animal
models. In Parkinson’s disease (PD), specifically, only rela-
tively effective symptomatic treatments are available. Such
treatments focus primarily on dopamine-mediated dys-
functions and do not affect the underlying degenerative
process, which extends beyond the dopaminergic system.
Thus, the impressive accumulation of information regard-
ing the underlying pathology, the molecules involved, and
the genetic background causing or contributing to the dis-
ease, has not impacted on clinically relevant interventions
[1]. The development of neuroprotective therapies that
slow, stop, or reverse neurodegeneration in PD has been
declared as the single most important unresolved issue in
the management of this disorder [2]. Attempts to stop the
neurodegenerative process in PD require an understand-
ing of the pathways leading to the selective cell death
which characterizes the disease. Over the years, several
such processes have been suggested, as detailed below.
It is now widely accepted that sporadic PD, like other
neurodegenerative diseases, has a complex pathogenesis
involving an interaction of several genetic contributions,
each with minor impact, and a number of environmental
factors [3]. This understanding could lead to a fatalistic
conclusion that it may be impossible to defeat the
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degenerative process. However, as shown herein, this
is not necessarily the case. Rather, it is likely that, at some
stage, convergence of several factors occurs leading to a
common downstream process (e.g. apoptosis of dopa-
minergic cells). We maintain that it is only the identi-
fication of the pathways leading to this final stage
which could allow us to effectively interfere with the
pathogenic process.
Recent attempts have been made to target α-synuclein
deposition, based on the assumption that α-synuclein
plays a causative role in neurodegeneration [4]. It is
possible, however, that different processes may lead to
α-synuclein accumulation. Moreover, it is unclear whether
it is really α-synuclein toxicity which is causing the de-
generation [5]. A rational therapy aimed at slowing the
progression of the disease (or its prevention) may target
α-synuclein, or go beyond it by identifying the processes
leading to its misfolding and deposition. Identification of
the molecular factors driving the pathogenesis of PD is
important in order to define, at the molecular level, not
only the disease predispositions but rather the pathogenic
processes in each individual patient [6]. However, the fact
that several different underlying processes exist, and
possibly converge, pose difficulties for the development
of a tailored therapeutic regime.
An impressive development in medicine in recent years
has been the attempt towards personalized, or individual-
ized, medicine, a term which has now been upgraded
to ‘precision medicine’ [7]. Naturally, medicine has al-
ways attempted to differentiate subjects based on their
background and needs, and to treat them accordingly.
In movement disorders, this has resulted in the differenti-
ation between PD, essential tremor, and progressive supra-
nuclear palsy, with important therapeutic implications.
Clinical decisions regarding the treatment of PD patients
with hypokinetic-rigid syndromes or those with tremor
have relied primarily on the clinical phenotype, aiming at
symptomatic improvement. Attempts to subdivide PD ac-
cording to predominant motor symptomatology, age of
disease onset, depressive affect, and cognitive performance
are based on arbitrary definitions and not on distinct
neuropathology [8] and neglect the importance of the
underlying pathogenic processes. The therapeutic ap-
proach to patients with PD is customized by targeting
the symptoms which are most troublesome to the individ-
ual patient [9]. Thus, the treatment of tremor-predominant
PD patients may differ from that of patients in whom rigid-
ity is the most disabling feature. Furthermore, therapeutic
decisions may depend on age, sex, and occupation of the
patient, as well as a host of other factors. However, all these
considerations only apply to symptomatic therapy. On the
other hand, precision medicine attempts to identify the
underlying molecular mechanisms responsible for the dis-
ease in an individual in order to develop an appropriate
therapy. This approach, as applied to PD, will be elaborated
below.
The human genome toolbox has expanded beyond the
simple identification of mutations or polymorphisms.
Transcriptomics, using microarrays and RNA sequencing,
can help to identify disease mechanisms, while proteomics,
pointing to specific protein profiles, can help in diagnosing
different disorders underlying PD. Importantly for the
present discussion, metabolomics can be used to identify
the underlying cellular metabolic changes occurring in
a given disease.
Sporadic PD does not have one single cause, and the
clinical features are the result of phenotypic convergence.
The separation of the different disorders which manifest
similar phenotypes is critically important when attempting
to reach and apply precision medicine.
Discussion
Genetics of PD
In the past decade, much research has focused on the
heredity of PD and the realization of the importance of
genetic contributions to the familial forms of PD [10].
The first dominantly inherited form of PD, named as
PARK1, is fully (or almost fully) penetrant, and is thought
to be related to a toxic effect of α-synuclein or to a loss of
functional α-synuclein [5]. In other forms of genetic parkin-
sonism, like PARK2, α-synuclein may not be involved at all.
However, the majority of PD cases are sporadic. In
these, genetic contributions are not clearly detected and,
at any rate, are likely to have a marginal role. Genome-
wide association studies have provided important infor-
mation on the genetics of sporadic PD [11], highlighting
the implication of several genes and the significant oc-
currence of population-specific heterogeneity. Most of
the identified genes were observed to have a rather
small effect and, thus, a large population was needed
for their identification [12, 13]. Clearly, several add-
itional genes could contribute to the risk of developing
PD, although these could not be detected by studying
individual cases.
The genes which have been identified as possibly related
to Mendelian forms of PD can be grouped as belonging
to at least four or five main classes (Table 1). Each of
these classes are defined by a different metabolic path-
way, including oxidative stress, lysosomal dysfunction,
proteasome-ubiquitin system dysfunction, and inflamma-
tion. Independent support of these abnormalities has long
been available [14–17].
The low risk associated with each of the genes involved
in the pathogenesis of sporadic PD likely indicates that
a convergence of factors, some genetic and others en-
vironmental, is needed to trigger the disease. Potentially,
dozens of risk alleles, each having a minute effect, are co-
operating to affect the liability to disease, and therefore
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the identification in a given person of one haplotype or an-
other is not likely to be helpful in either estimating the risk
of developing sporadic PD or its rate of progression and is
thus an unlikely target for intervention. In order to affect
the neurodegenerative process, it is necessary to identify
the biochemical process to which each gene contributes.
Monogenic diseases suggest that separate processes may
occur in different PD patients (Table 1).
Genomics
Information from genomics is theoretically therapeutically
useful in cases having primarily a strong genetic back-
ground, particularly those with Mendelian inheritance. For
example, genetic manipulation could replace a mutated
α-synuclein gene by a normal one. Although this is still
not applicable in humans, there is no apparent theoretical
reason why this could not be performed, or why an abnor-
mal α-synuclein gene could not be silenced [18]. This tech-
nique has already been performed in experimental animals.
Thus, Kachroo and Schwarzschild [19] reported that dis-
ruption of the adenosine A2A receptor gene may protect
experimental animals from dopaminergic cell loss induced
by α-synuclein overexpression. Such an intervention, if and
when successfully implemented in humans, could shift the
focus from reactive to preventive healthcare. However,
while this therapy would be relevant to individuals carrying
a duplicated (and perhaps mutated) α-synuclein gene, it
would not be relevant to most PD patients. In cases with a
genetic background, the situation is more complex. For ex-
ample, for LRRK2 mutation carriers, it is not clear what the
underlying molecular process responsible for the disease is,
and whether in a given disease-associated genotype the mu-
tated gene leads to increased enzymatic kinase activity or
reduces it, let alone which molecules phosphorylated by
LRRK2 are relevant to the development of PD.
Epigenomics
The complexity of sporadic PD is underlain by the fact
that the disease is caused in different people by a variable
contribution of genetic polymorphisms and environmental
factors. Environmental factors might exert their effect in
several ways, for example, through a direct toxic effect
(e.g. agricultural pesticides or herbicides). However, it is
increasingly recognized that these environmental factors
might operate by modifying genetic pathways. Rather than
altering DNA itself, these factors may operate epigeneti-
cally, by changing the expression of certain genes. The
field of epigenetics attempts to explore the mechanisms by
which environmental factors interact with genetic expres-
sion. These epigenetic effects may occur at any age, but
older people are more vulnerable. For instance, oxidative
DNA damage increases in the aged due to the reduced ef-
ficiency of repair enzyme systems. This may explain the
fact that, even in cases with a genetic background, PD
manifests itself typically in middle life or later. Presumably,
even in cases with Mendelian dominant or recessive in-
heritance, a ‘second hit’ is needed, with environmental
stressors perhaps exerting an epigenetic effect.
Biomarkers
Biomarkers can include changes in body chemistry, anat-
omy, or physiology in genes and how they are regulated,
and even subtle differences in a person’s behavior, but
may also serve as important clues to the etiology of the
disease. For example, certain antibodies in the blood can
be biomarkers for different types of infections. In recent
years, several attempts have been made to identify bio-
markers for PD [20]. Acknowledging the difficulties in
diagnosing PD based on clinical criteria, biomarkers
could help in several ways, for example, in the prognos-
tication or inclusion into therapeutic studies, but also in
detecting early clinical and even preclinical cases and
allowing early intervention. The attempt to identify such
biomarkers has traditionally been based on the assump-
tion that PD is etiologically homogeneous. As mentioned
above, this assumption may be wrong. If what is presently
included under the PD umbrella are clinical phenotypes
originating in different mechanisms [21], the failure to find
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such biomarkers is not surprising. If indeed PD is etio-
logically and pathogenetically heterogeneous, biomarkers,
which will be applicable to all cases, if identified, are likely
to indicate downstream changes.
Metabolomics
Several biochemical/metabolic pathways, which may lead
to an identical (or very similar) clinical PD phenotype,
have been suggested over the years. These include ab-
normalities of mitochondrial function or oxidative stress
in several genetic forms (e.g. PINK1) [22], while in others,
impaired protein degradation (ubiquitin-proteasome sys-
tem, as in PARKIN mutation carriers) [23] or lysosomal
dysfunction (as in GBA mutation carriers; Table 1) [24]
may occur. Metabolomics research is important because it
can establish the relevant biochemical pathway involved in
disease pathogenesis in a given patient regardless of the
primary cause, which can help to identify interventions
which could modulate these pathways. The metabolomic
approach is obviously helpful in patients with monogenic
disease pointing to the specific effect of the mutation. For
example, the dysfunction by which SNCA changes cause
PD has not been deciphered, although indications of pro-
tein mishandling, mitochondrial damage, and oxidative
stress, as well as lysosomal dysfunction and inflammation
have been suggested [25]. Thus, the identification of
SNCA mutations by itself still does not lead to identifica-
tion of the relevant mechanisms, which is required in order
to develop a specific therapy against α-synuclein-triggered
neurodegeneration. Since it is difficult to find the exact
molecular mechanism through which this (and other)
mutations operate, it could be useful to find intermediate
steps, neither high upstream nor low downstream. This
approach could be particularly useful in those patients
with a complex disease pathogenesis where a constellation
of genetic polymorphisms and environmental factors
contribute to disease pathogenesis.
Lysosomal dysfunction has been identified as an im-
portant mechanism of the pathogenesis of PD associated
with GBA mutations [26, 27] and other genetic forms
[28], but it has also been suggested to be involved in
sporadic PD [29].
Mitochondrial dysfunction has long been suspected
to be involved in PD pathogenesis [30–33]. Nevertheless, if
mitochondrial dysfunction only applies to a subgroup of pa-
tients, this has important clinical implications. Treatment
with Coenzyme Q-10 (a naturally occurring antioxidant
that affects mitochondrial depolarization and acts as an
electron transporter for mitochondrial complexes I and II)
has been studied in PD based on the assumption that this
drug may ameliorate neuronal oxidative stress [34, 35].
Additional approaches to this target have recently been
suggested [36]. However, clinical studies with pioglitazone
have been disappointing [37], possibly since they included a
heterogeneous PD population. A more appropriate ap-
proach could have been to focus on those individuals
with evidence of mitochondrial dysfunction, who are the
rational targets for correcting this pathology.
Inflammatory changes have also been proposed to be
associated with the pathophysiology of PD [16, 38–40]
and, while the importance of this process is not well
understood, it is plausible that it also differs among individ-
ual patients. Thus, in those subjects in whom inflammation
is exerting a significant impact on the disease mechanism,
attempting to quench it could be rewarding.
Metabolomic therapy, aimed at the presumed pathogenic
mechanism, should have disease-modifying properties,
slowing or stopping disease progression, but may look
completely inefficacious if the selected endpoints in a
study are short-term symptomatic effects. Demonstra-
tion of the usefulness of the metabolomic approach was
provided recently by Johansen et al. [41], who showed
that the metabolomic profile of PD patients carrying
the LRRK2 G2019S haplotype differed from that of cases
with sporadic PD. To some extent, LRRK2 G2019S
carriers with PD also differed from clinically unaffected
carriers.
Therapeutic implications
An attempt to identify a single disease-modifying ther-
apy which will benefit all PD patients may be naïve, as
different patients may have completely different under-
lying processes. Therefore, if specific interventions are to
be developed, the pathogenic process leading to PD
needs to be understood for each individual; this is the
concept of precision medicine [7]. Sporadic cases are
assumed to result from a combination of polygenic in-
heritance, interacting with a variety of environmental
factors (some possibly protective, e.g. smoking, coffee
or tea drinking [42] whilst others damaging, e.g. head
trauma), acting in a concerted way. The implications of
precision medicine are that, in terms of neuroprotective
therapy at least, one should move ahead from phenotype
diagnosis to characterization of the underlying pathogen-
etic process in each individual patient. This could lead to a
rational approach to develop a disease-modifying therapy.
Summary
PD is a complex disorder and the clinical manifestations
of sporadic PD are likely to be due to phenotypic con-
vergence, where the disease is caused by multiple contri-
butions of genetic and environmental factors that may
differ in each patient. It is therefore not surprising that
animal studies have failed to find a disease-modifying
therapy for the human disease. Such studies typically
employ a single animal strain, with a distinct and unique
pathogenesis, and therefore they cannot be expected to
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be relevant to sporadic PD patients in whom the disease
develops through different pathogenetic pathways.
The enormous advances made in biology, genomics,
transcriptomics, proteomics, and metabolomics allow a
fresh exploration of neurodegenerative diseases and illu-
minate PD pathogenesis, facilitating a pathway-oriented
approach which may provide individual prognostication
and intervention to affect disease progression.
The realization that PD is not a disease but rather a
syndrome, defined by its clinical phenotype and caused
by several distinct mechanisms [18, 36], has several logical
consequences. Firstly, attempts to identify biomarkers for
the ‘disease’ will either fail or identify processes in the final
stages of the disease, e.g. apoptosis, which are of limited
clinical relevance. Similarly, it is possible that toxic sub-
stances only affect susceptible people. For example, a
mitochondrial toxin is more likely to damage individuals
in whom mitochondrial function is (genetically) com-
promised. More importantly, development of disease-
modifying therapies depends on identifying the underlying
pathogenesis; it is unlikely that any such therapy will be
discovered if different pathogenetic mechanisms operate
in different individuals, as long as the study would include
a heterogeneous combination of cases. The development
of such a disease-modifying therapy would require the
identification of biomarkers for the pathogenesis, e.g. oxi-
dative stress, the selection of patients with this form of
pathogenesis, and their treatment with a relevant drug,
e.g. an anti-oxidative drug. Similar suggestions have been
recently brought forward [39]. In the era of personalized
medicine [7], an attempt must be made to identify early
changes. These could include genetic polymorphisms
or epigenetic factors, each of which can lead to specific
therapies, e.g. pharmacogenomic interventions.
Finally, it is possible that the different pathogenic
mechanisms seen in monogenic PD cases are closely
interacting, for example, protein mishandling affects
mitochondrial dysfunction and vice versa. If that is the
case, there could still be a single predominant patho-
genic mechanism regarded as the ‘primary’ step in a
given individual. Otherwise, disease modification will
require concerted action in several fronts, acting on
several pathogenic processes simultaneously, such as by
multifunctional therapies or drug cocktails. If this is the
case, the prospects of developing disease-modifying
therapies are considerably diminished.
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